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Abstract
We aimed to investigate fractalkine (CX3CL1) protein expression in wild type (wt) retina and its alterations during retinal
degeneration in mouse model (rd10) of retinitis pigmentosa. Forms of retinal protein CX3CL1, total protein and mRNA levels
of CX3CL1 were analyzed at postnatal days (P) 5, 10, 14, 22, 30, 45, and 60 by Western blotting and real-time PCR. Cellular
sources of CX3CL1 were investigated by in situ hybridization histochemistry (ISH) and using transgenic (CX3CL1cherry) mice.
The immunoblots revealed that in both, wt and rd10 retinas, a membrane integrated ,100 kDa CX3CL1 form and a cleaved
,85 kDa CX3CL1 form were present at P5. At P10, accumulation of another presumably intra-neuronal,95 kDa form and a
decrease in the ,85-kDa form were observed. From P14, a ,95 kDa form became principal in wt retina, while in rd10
retinas a soluble ,85 kDa form increased at P45 and P60. In comparison, retinas of rd10 mice had significantly lower levels
of total CX3CL1 protein (from P10 onwards) and lower CX3CL1 mRNA levels (from P14), even before the onset of primary
rod degeneration. ISH and mCherry reporter fluorescence showed neurons in the inner retina layers as principal sites of
CX3CL1 synthesis both in wt and rd10 retinas. In conclusion, our results demonstrate that CX3CL1 has a distinctive course of
expression and functional regulation in rd10 retina starting at P10. The biological activity of CX3CL1 is regulated by
conversion of a membrane integrated to a soluble form during neurogenesis and in response to pathologic changes in the
adult retinal milieu. Viable mature neurons in the inner retina likely exhibit a dynamic intracellular storage depot of CX3CL1.
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Introduction
Retinitis pigmentosa (RP) constitutes a large, heterogeneous
group of inherited retinal neurodegenerative conditions. The
phenotype is characterized by an initial rod-cone dystrophy
followed by an aberrant remodeling of the surviving retina that
corrupts visual processing [1,2]. Retinal remodeling is a universal
pathologic process subsequent to retinal degenerative disease that
results in deafferentiation of the neural retina from photoreceptor
input. Downstream neuronal elements respond to loss of input
with a phased revision of retinal structure and function found at
the molecular, synaptic, cell, and tissue levels and involving all cell
classes in the retina, including neurons and glia [3,4].
Within the nervous tissue, neurons, express ‘‘on and off‘‘ signals
to maintain their milieu through the release of factors that control
innate immune cell function, including microglia [5–8]. Microglia
are resident cells of the nervous tissue involved in regulatory
processes critical for development, maintenance of the neural
environment, injury and repair and, as such, are sensors of events
occurring within their immediate environment [9]. Degenerating
neurons release several signaling molecules, including nucleotides,
cytokines and chemokines, to recruit microglia and enhance their
activities [10,11]. It was demonstrated that all retinal microglial
cells express a receptor for CX3CL1, a chemokine receptor 1
(CX3CR1) [12].
Fractalkine (also known as neurotactin, fractalkine ligand 1,
CX3CL1) is expressed as multi-domain membrane-spanning
molecules consisting of a chemokine domain with CX3C motif,
a flexible highly glycosylated mucin-like stalk, a transmembrane
domain and a short cytoplasmic domain [13]. It is one of the
neuroimmune regulatory proteins that is abundantly expressed on
neurons and signals through its single G-protein-coupled receptor
(CX3CR1), exclusively on microglia [14–20]. Endogenous ex-
pression of CX3CL1 produces a membrane integrated monomeric
isoform [21] that can be cleaved by several proteases including a
disintegrin and metalloproteinase (ADAM) family, ADAM-10,
ADAM-17 [22–24] and cathepsin S [25]. Such cleavage yields a
soluble isoform of CX3CL1, comprising of the mucin-like stalk
and the chemokine domain. Both isoforms of CX3CL1 have been
shown to ligate CX3CR1 [22,23,26,27]. CX3CL1 directly induces
various microglial functions including migration [14], proliferation
[28], inhibition of Fas-ligand-induced cell death [29], glutamate-
induced neurotoxicity [30,31] and inhibition of proinflammatory
cytokines production [5,16]. Recently, it was shown that the
soluble form of CX3CL1 directly enhances microglial clearance of
degenerated neuronal debris [31]. Thus, CX3CL1 represents a
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unique chemokine that contain properties of both chemoattractant
and adhesion molecules, since it can exist either as a soluble
protein or a membrane integrated molecule, playing a pivotal role
in signaling between degenerating neurons and microglia [32].
However, the individual signaling functions of each CX3CL1
isoform under physiological and neurodegenerative conditions are
not fully understood.
Strong evidence indicates that soluble fractalkine prevents N-
Methyl-D-aspartate-neurotoxicity [18,27,33]. It controls glutama-
tergic activity by inhibiting excitatory postsynaptic currents
[33,34], and negatively regulates neuronal migration; while
promoting the adhesion to extracellular matrix [35]. However,
the extent, to which each of these mechanisms is involved in the
physiological role of fractalkine, may vary between normal,
inflammatory and neurodegenerative conditions, at different
stages of life and/or during diseases states [36–38].
In contrast to the growing amount of research data from the
brain, not much is known about the potential roles of CX3CL1 in
the retina. The purpose of the present study was therefore to
analyze in detail, the CX3CL1 expression in normal and
degenerating mouse retina. As a model of autosomal recessive
RP, we used in our study rd10 mice bearing a spontaneous
missense point mutation in exon 13 of the beta-subunit of the rod
cGMP phosphodiesterase gene, a member of the phototransduc-
tion cascade [39]. Mutations in the cGMP phosphodiesterase gene
have been identified in approximately 5% of cases in human
patients with autosomal recessive RP [40].
In order to elucidate possible alterations of the cellular
communication between neurons and microglia involving cyto-
kines and chemokines, such as fractalkine, we characterized forms
of CX3CL1 protein, estimated total protein and mRNA levels of
CX3CL1 and the cellular source of CX3CL1 in the retinas at
normal and pathological states.
We focused on a time window from birth to young adulthood,
encompassing in rd10 mice onset and late stages of rod and cone
cell degeneration along with the early phase of second and third
order neuron remodeling [39,41–45].
Materials and Methods
Animals
Rd10 homozygous (rd10) mice in C57BL/6J background were
obtained from Charles River Laboratories (Germany). Wild-type
(wt) background control C57BL/6J mice were imported from
Jackson Laboratories (USA). Rd10 and C57BL/6J mice were
intercrossed to obtain heterozygous animals from which homozy-
gous rd10 mice and control wt littermates were obtained. These
animals were used as breeders for generating the mice used in the
experiments. Additionally, eye samples of CX3CL1cher-
ry:CX3CR1gfp transgenic mice expressing red and green fluores-
cent reporter genes under the respective control of the CX3CL1
and CX3CR1 promoters [46,47] were also characterized which
were kindly provided by Steffen Jung, The Weizmann Institute of
Science, Rehovot, Israel.
Rd10 and wt mice were kept under 12-hour light/dark cycle
with lights on at 7:00 am in a temperature (2261uC) and humidity
(5565%) controlled room. All cages were placed on the lower shelf
of an IVC rack (Maximizer, Ehret, Austria) with reduced light
illuminance of 30 Lux, as measured with Gossen MAVOLUX
5032 B USB Digitales Luxmeter (Elektrohandel Thiele, Germany).
The cages contained wood shavings as bedding and a plastic tube
for environmental enrichment. Mice were fed ad libitum with
standard chow and supplied with mildly acidified water. For
collection of retinas and brain samples, mice at postnatal day 5
(P5) were sacrificed by decapitation. Older ones (at P10, P14, P22,
P30, P45 and P60) were pre-treated by CO2 asphyxiation,
immediately followed by cervical dislocation. The animals’ health
status was monitored throughout the experiments by a health
surveillance program according to Federation of European
Laboratory Animal Science Associations (FELASA) guidelines.
100 mice were utilized for this study and 86 were included and
completed. 14 animals were excluded because of instrumentation
or technical failure during sample preparation.
Ethics Statement
All procedures of animal handling conformed to the European
Union guidelines for the use of laboratory animals (Directive
2010/63/EU of the European Parliament and of the Council) and
to the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Animal care and all experimental proce-
dures were approved by the Animal Experimental Committee of
the Medical University of Vienna, and by the Austrian Ministry of
Science (License No. BMWF-66.009/0222-II/3b/2013). Al-
though Rd10 mice exhibited postnatal retinal degeneration, due
to their low-grade phenotype no special requirements on
amelioration of suffering of these mice were a priori required.
Tissue Preparation
The animals’ eyes were rapidly enucleated, hemisected and,
after dissection of sclera-choroid tissue with fine forceps, the
retinas were detached from the pigment epithelium. For real-time
PCR the right and left isolated retinas of each animal were pulled
together, placed into screw cap cryotube and were immediately
frozen at 280uC. For Western blot studies, the retinas were
initially prepared in the same way as for real-time PCR. Both left
and right retinas of each animal were collected separately to
compose the duplicates of a single mouse. Also the brains were
rapidly removed, immersed into an ice-cold sterilized 0.01 M PBS,
and the hippocampal dentate gyrus subregion was dissected out.
Retina and brain tissues were placed with fine clean forceps into
Eppendorf microcentrifuge tubes, then snap frozen in liquid
nitrogen and stored at 280uC. For histology and in situ
hybridization the eyes were rapidly enucleated, fixed in 4%
paraformaldehyde for 1 hour, then conjunctiva, cornea, crystalline
lens and vitreous were dissected and discarded. After fixation, the
tissues were washed with PBS. Eye-cups and rostro-caudal coronal
5 mm thick blocks of mouse brains containing the hippocampal
area were either frozen for cryosectioning or embedded in
paraffin.
Western Blot Analysis
The retinas and brains were homogenized by BioVortexer
homogenizer in ice-cold lysis buffer (10 mM Tris-HCl, pH 7.5;
67 mM NaCl) containing 1% SDS, 0.1 mM EDTA, protease
inhibitor cocktail (Roche Diagnostic, Basel, Switzerland, Cat.#
04693124001), and phosphatase inhibitors 1 mM sodium ortho-
vanadate, 1 mM sodium fluoride, 0.5 mM tetrasodium diphos-
phate. After 30 minutes incubation on ice, lysates were cleared by
centrifugation, and protein concentration was determined by BSA
protein assay (Pierce Biotechnology, Rockford, IL, USA). Equal
amounts of protein (10 mg/sample/lane) were loaded onto Tris-
Glycine 12% SDS PAGE run under reducing conditions. As a
marker, Spectra Multicolor Broad Range Protein Ladder (Cat.#
26634, Thermo Fisher Scientific, Waltham, MA, USA) was used.
Upon electrophoretical transfer to PVDF membranes (Cat.#
T830.1, Carl Roth GmbH, Germany), blots were incubated for
1 hour with 5% non fat dry milk in Tris-buffered saline containing
0.1% Tween 20 and incubated overnight at 4uC with a polyclonal
Fractalkine Protein Expression in Mouse Retina
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rabbit anti-CX3CL1 antibody raised against the e. coli-expressed
extracellular domain (aa1-85) of human fractalkine and cross
reacting with mouse and rat CX3CL1 (0.3 mg/mL, Cat.#
ab25088 Abcam, Cambridge, UK). Upon treatment with HRP
conjugated donkey anti-rabbit IgG ECL antibody (1:4000, GE
Healthcare, Chalfont St Giles, Buckinghamshire), enhanced
chemiluminescence (ECL) analysis (GE Healthcare Europe
GmbH) was imaged with FluorChem HD2 detection system
(Alpha Innotech, San Leandro, CA, USA). For quantification,
stripped blots were re-probed with mouse monoclonal anti-
glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) prima-
ry antibody (0.2 mg/mL, Cat.# AM4300, Life Technologies,
Carlsbad, CA, USA) followed by secondary HRP conjugated anti-
mouse IgG antibody (1:10000, GE Healthcare Europe GmbH).
All experiments were performed in biological (five mouse retinas)
and technical (five replicates per mouse) quintuplicates. Densi-
tometry was performed using Image J analysis software version
1.44, developed at the U.S. National Institutes of Health and
available on the internet at http://rsb.info.nih.gov/nih-image/.
Antibody Control Experiments
The polyclonal rabbit anti-CX3CL1 antibody was tested for
signal specificity with antigen-peptide neutralization (competition)
assay. The preadsorption was performed on identical immuno-
blots. Antibody was diluted in TBST. The compositions of the
blocking solution and the final antibody concentrations were as
stated above. Each of these antibody solutions was then divided in
2 aliquots to obtain pairs of identical solutions. A positive control
for the antibody detection, consisting of an ,70-kDa form
recombinant human fractalkine peptide (aa 25-100), lacking the
signal peptide, mucin-like stalk, both transmembrane and the
carboxy-terminal domains (PeproTech Cat.# 300-31), was added
at 0.6 mg/mL to one aliquot from each pair. The immunoblots
were then incubated overnight at 4uC before being processed for
immunolabeling as described above.
Real-time PCR
Total RNA was isolated by standard procedure using Trifast
(PeqLab Biotechnology, Erlangen, Germany) and Precellys 24
homogenizer (PeqLab Biotechnology), followed by reverse tran-
scription using the MuLV-reverse transcriptase I in the presence of
RNAse inhibitor and oligo dT16 primers (Life Technologies).
Real-time PCR was accomplished in Step One Plus Real-Time
PCR Cycler (Life Technologies) using FastStart SYBR Green
Master Mix (Life Technologies) and CX3CL1 specific primers
(forward 5’-CGC GTT CTT CCA TTT GTG TA-3’ and reverse
5’-CTG TGT CGT CTC CAG GAC AA-3’ CX3CL1 primers
resulting in a 169-bp amplicon) by normalizing to the expression
of b2-microglobulin (5’-GAT GAG TAT GCC TGC CGT GTG-
3’ and 5’-CAA TCC AAA TGC GGC ATC T-3’ resulting in a
114-bp amplicon).
Immunohistochemistry
At least three rd10 and wt mice were studied at selected time
points. Eye samples derived from transgenic (CX3CL1cherry:
CX3CR1gfp) mice were collected in a similar way. As controls,
brain samples containing hippocampal dentate gyrus subregion
were collected and prefixed as above. After fixation, tissue samples
were washed with PBS, submerged into 20% sucrose and mounted
in Tissue-Tek O.C.T. Serial cryo-sections (10 mm) were permea-
bilized in PBS containing 0.5% Triton X-100, blocked in 10%
BSA in PBS containing 0.25% Triton X-100 for 1 hour at room
temperature and exposed to primary antibodies overnight at 4uC.
Mouse monoclonal anti-mCherry antibody (1:300, 1C51, Cat.#
ab125096 Abcam, Cambridge, UK) and rabbit polyclonal anti-
GFP antibody (1:1000, Cat.#6556 Abcam, Cambridge, UK) were
used to immunolabel mCherry and GFP expressing cells,
respectively. After washing with PBS, sections were exposed to
secondary antibodies for 1 hour at room temperature, then
washed with PBS, counterstained with DAPI (Sigma-Aldrich,
Saint Louis, MO, USA, Cat.# A3648) and mounted in Fluoro-
Gel aqueous medium (Science Services GmbH, Mu¨nchen,
Germany). Microscopic analysis was performed either by Eclipse
E600 (Nikon, Tokyo, Japan) or Axiovert 200 M (Carl Zeiss, Jena,
Germany) microscopes. In the latter, image acquisition was
enhanced using a Zeiss Apotome Confocal System. Immunohis-
tochemical controls were performed by omission of either the
primary or secondary antibodies.
RNA probes (riboprobes)
The cellular localization of fractalkine mRNA was detected with
digoxigenin-labeled single-stranded cRNA probes using in situ
hybridization. ORF clone of Mus musculus CX3CL1 cDNA was
subcloned into a plasmid pGEM-T vector (Sino Biological Inc.,
China, Cat.# MG50917-G) and propagated in E. coli strain
(XL1-Blue supercompetent cells, Stratagene, USA, Cat.#
200236). The DNA was purified using the PureLink HiPure
Plasmid DNA Midiprep Kit (Invitrogen, USA, Cat.# K2100-15),
linearized with the appropriate restriction enzyme digestion and
extracted from preparative agarose gel using PCR Clean-Up
System (Promega, USA, Cat.# A9282). The antisense and sense
strand negative control riboprobes were generated by in vitro
transcription from 1 mg of the linearized DNA. Purified DNA
templates were used for a transcription with SP6 (Cat.# P1085)
and T7 (Cat.# P2077) RNA polymerases (Promega, USA) and
DIG-RNA-labeling kit (Roche Diagnostics GmbH Applied
Science, Vienna, Austria, Cat.# 11175025910), giving about
10 mg labeled RNA per mg of template. The riboprobes were
purified through a Sephacryl S-300 MicroSpin column (GE
Healthcare, Product code 27-5130-01) to remove unincorporated
digoxigenin-labeled nucleotides. The incorporation of DIG label
into the RNA probes was estimated on dot blot by using
colorimetric assay, similar to the in situ hybridization detection
method. Dots (1 mL) of the probe at serial dilutions were spotted
on a nylon membrane, dried, and UV-linked for 2 min. Sense
CX3CL1 cRNA was used as background control. To test for
nonspecific binding of the secondary detection systems, hybrid-
ization was also performed in the absence of specific probes.
Pretreatment of Sections for In Situ Hybridization
For paraffin sections slides were pre-coated with 2%, 3-
aminopropyltriethoxysilane (Sigma-Aldrich, St. Louis, MO,
USA, Cat.# A3648) and air-dried. After dewaxing, 3 mm sections
were postfixed in 4% paraformaldehyde in 0.1 M phosphate
buffer and treated with 0.2 M HCl. Proteinase K (10 mg/mL)
(Sigma-Aldrich, St. Louis, MO, USA, Cat.# P2308) digestion was
performed at 37uC in 0.5 M Tris-HCl buffer (pH 7.4) for 5 min.
The enzymatic reaction was stopped with Tris-HCl buffer at 4uC.
Nonspecific staining was prevented by acetylation (0.5% acetic
acid anhydride in 0.1 M Tris-HCl buffer, pH 8.0) for 10 min. The
sections were then dehydrated in graded ethanol and were rinsed
in chloroform. Frozen 8 mm sections were air-dried and processed
in similar way as paraffin sections.
In Situ Hybridization
In situ hybridization on cryosections of retinal or brain samples
or paraffin-embedded brain sections was performed as described
previously [48,49]. Briefly the probes were denatured, and the
Fractalkine Protein Expression in Mouse Retina
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probe solution was pipetted onto the slides, then covered with a
coverglass and placed on a hot plate at 95uC for 4 min. The
hybridization solution contained: 47% deionized formamide, 26
SSC, 10% dextran sulfate, 0.01% sheared salmon sperm DNA
(Sigma-Aldrich, St. Louis, MO, USA, Cat.# D7656), 0.02% SDS,
and the labeled probes used in 1:100 working concentration, as
determined in dot-blots. Hybridization was performed at 65uC for
16–20 h. After hybridization, the sections were washed in 50%
deionized formamide (N, N-dimethylformamide, Sigma-Aldrich,
Saint Louis, MO, USA, Cat.# D4551) in 16 SSC at 55uC for
1 hour. Unsaturated binding sites were blocked with blocking
reagent. Digoxigenin labeling was detected with alkaline phos-
phatase-conjugated anti-digoxigenin antibody at 1:500 (antidigox-
igenin AP, Fab fragments, Roche Diagnostics GmbH Applied
Science, Cat.# 11093274910), in 0.5% blocking reagent (Roche
Diagnostics GmbH Applied Science, Cat.# 11096176001), with
10% fetal calf serum. Development of the in situ hybridization was
performed in 4-nitro blue tetrazolium chloride (Roche Diagnostics
GmbH Applied Science, Cat.# 11585029001) and 5-bromo-4-
chloro-3-indolyl phosphate (Roche Diagnostics GmbH Applied
Science, Cat.# 10760994001) for 20 hours. The sections were
counterstained by hemalaun and mounted into GelTol aqueous
medium.
Statistical Analysis
Values are presented as mean 6 SEM with significance
determined at p,0.05. Statistical significance was evaluated by
Student’s unpaired two-tailed t test, and by Pearson product-
moment correlation coefficient using Graph Pad Software
available on the internet at http://www.graphpad.com.
Results
CX3CL1 Protein Forms Revealed by Western Blotting
Using an antibody recognizing the extracellular domain of
CX3CL1, three CX3CL1 bands of molecular weights ,100 kDa,
,95 kDa and ,85 kDa were detected. At developmental day 5,
fractalkine full-length ,100 kDa and cleaved ,85 kDa protein
forms were present in both wt and rd10 retinal lysates at
comparable levels (Fig. 1A). As development of the retina
progressed (at P10), the tendency of retinal neurons toward
accumulation of another ,95 kDa protein form in both wt
(Fig. 1B) and rd10 (Fig. 1C) became evident. Simultaneously, at
P10 the ,85 kDa protein form had dropped to the levels below
detection limit in both rd10 and wt retinal lysates. From P14
through adulthood, a band at ,95 kDa was dominant in wt
(Fig. 1D and E) and was also highly expressed in rd10 retinas
(Fig. 1F and G). At P45 and P60 the shorter ,85-kDa form was
clearly detected again in rd10 retinas indicating increased
proteolytic cleavage compared to the wt retinas (Fig. 1G).
Relative occurrence of CX3CL1 Protein Forms
Analysis of the expression of CX3CL1 protein forms, as
percentage of the total protein level (Fig. 1H-I), revealed that
full-length ,100 kDa and cleaved ,85 kDa forms are present at
comparable levels in wt and rd10 retinas at P5 (p,0.05). From
P10 through P60, the initial balance is changing toward an
increase of a ,95 kDa form in normal (wt) retinas (p,0.05).
Remarkably, the ,95 kDa appeared to be the only form clearly
detected in wt retina at P30 to 60. Interestingly, from P10 through
P60, the ,95 kDa protein form in rd10 retina is present at lower
percentage rate than in wt (p,0.05). When the ,85 kDa band
increased in rd10 at P45–60, it appeared that ,95 kDa and
,100 kDa forms are present at comparable levels (p,0.05).
To assess the relationship between the three forms of fractalkine
protein, we computed a Pearson product-moment correlation
coefficient (r). We showed a positive correlation among the
detected CX3CL1 bands in rd10 retinas (as summarized in Fig.
legend 1). We further proved the specificity of anti-CX3CL1
antibody used in Western blots and revealed the absence of sex-
related differences in retinal samples of rd10 and wt mice (Fig. S1).
Finally, we demonstrated the suitability of the usage of GAPDH as
endogenous control for CX3CL1 protein expression normaliza-
tion in Western blots (Fig. S2). Even though, using a set of well-
characterized antibodies and lectins, we observed, consistently
with other studies [39,41,43–45,50,51] the expected degeneration
over time of photoreceptors and second order neurons in the
retina of rd10 mice (data not shown), the relative density of
GAPDH remained roughly constant in total retinal protein
homogenates. Thus, we can conclude that usage of GAPDH as
internal control assured a reliable detection of alterations in levels
of CX3CL1 protein in Western blots of retinas of rd10 and wt
mice.
Decrease of both, CX3CL1 Protein and mRNA in Rd10
compared to Wt Retinas
CX3CL1 total protein in wt retinas was relatively low at P5,
increased at P10, peaked at P14 and remained at relatively high
constant levels at P22, P30, P45 and P60. In rd10 retinas, levels of
CX3CL1 protein were comparable to wt retinas at P5. However,
they decreased at P10 and remained considerably low in
comparison to wt retinas at all subsequent analyzed time points
(P14, P22, P30, P45 and P60) (Fig. 2A). Thus we can conclude
that levels of CX3CL1 in rd10 mice were significantly lower, in
comparison with wt retinas, as early as postnatal age, at P10.
CX3CL1 mRNA levels revealed that in wt retinas mRNA
showed an increase at P10 as compared to P5. It further increased
at P14 and remained relatively constant until P60. In rd10 retinas,
CX3CL1 mRNA levels were comparable to wt retinas only at P5
and P10 and from P14 onwards, they were significantly lower
compared with wt retinas (Fig. 2B). Overall these results demon-
strate that CX3CL1 mRNA (from P14), and total protein levels
(from P10), are significantly lower in rd10 compared to wt retinas.
Localization of CX3CL1 mRNA Expressing Cells by in situ
hybridization
To define the cellular source of CX3CL1 in the retina, we
accomplished in situ hybridization experiments on retinal tissue
sections of rd10 and wt mice. The strongest labeling was displayed
in a subpopulation of neurons within the ganglion cell layer, while
the outer nuclear (photoreceptor) layer was devoid of CX3CL1
expression in both wt and rd10 retinas at all examined time-points.
The analyses revealed CX3CL1 mRNA expression in neurons of
inner- and outermost-subtiers of the inner nuclear layer and in the
ganglion cell layer in both wt and rd10 retinas (Fig. 3A-D), while
no expression was detected in the distal retina or in cells associated
with the retinal vasculature. In control brain samples of wt mice,
high levels of CX3CL1 mRNA were detected in pyramidal cells
within the hippocampal formation (Fig. 3E-F) and the grey matter
of the cerebral cortex (Fig. 3G). As expected, parallel paraffin
brain and retinal cryosections hybridized with a control sense-
transcribed CX3CL1 cRNA probe of equal specific activity did
not reveal signals above background levels (data not shown).
Overall, our in situ hybridization experiments revealed an
unambiguous neuronal expression of CX3CL1 mRNA in rd10
mouse retina at P22 and P30.
Fractalkine Protein Expression in Mouse Retina
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Figure 1. Western blot analysis of fractalkine protein expression in mouse neural retina at P5 until P60 being representative of five
independent experiments. Blots were re-probed with anti-GAPDH antibody. (A). Fractalkine membrane integrated (100-kDa) and soluble (85-kDa)
protein forms are present in both control (wt) and rd10 retina lysates during development at P5. (B). Accumulation of presumably intracellular (95-
kDa) protein form is seen in both wt (B) and rd10 (C) developing neural retina at P10. Remarkably, no cleaved (85-kDa) protein form was associated
with membrane integrated (100-kDa) form in both rd10 and wt retina lysates at P10. Both wt and rd10 retinas show lower to beneath detection level
of 100-kDa form and higher level of 95-kDa form at P14 through P60 (D-G). Increased level of 85-kDa form is clearly detectable in rd10 retinas at P45
and P60 (G). Histogram showing relative percent levels of each of the three CX3CL1 protein forms in wt retina (H) and degenerating rd10 retina (I).
Data are expressed as percent of densitometric arbitrary units. Values are mean 6 SEM, (n = 5). In rd10 retinas, positive correlation between the
relative levels of a ,100-kDa and corresponding 85-kDa bands was found at P45 and P60 (Pearson product-moment correlation coefficient r = 0.683,
n = 12, p = 0.014 in RD10 retina at P45 and r = 0.882, n = 9, p = 0.0017 at P60) as well as for the relative levels of a 100-kDa and 95-kDa bands (r = 0.928,
n = 11, p,0.0001 at P14, r = 0.861, n = 9, p = 0.0029 at P22, r = 0.892, n = 9, p = 0.0012 at P30, r = 0.966, n = 12, p,0.0001 at P45, and r = 0.628, n = 12,
p = 0.0288 at P60 in rd10 retina). The degree of association between the levels of 95 kDa and 85 kDa protein band was r = 0.712, n = 12, p = 0.0094 at
P45 and r = 0.907, n = 9, p = 0.0007 at P60. It was not, however, possible, to make similar analysis for the wild type retina samples, as the level of the
,95-kDa protein form was the highest and the levels of cleaved and full-length forms were far below the limit of detection.
doi:10.1371/journal.pone.0106562.g001
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Analysis of CX3CL1 Expression in Control Transgenic
Mice
To further characterize CX3CL1 and CX3CR1 expression
pattern in the retinas, we made use of transgenic (CX3CL1cher-
ry:CX3CR1gfp) mice [46]. Fluorescence analysis of cryosections
of retinas derived from these revealed a regionally restricted
CX3CL1/Cherry signal. It was present exclusively in the ganglion
cell and inner nuclear layers of the retinas, indicating high level of
the CX3CL1 promoter activity in at least a portion of these
neurons (Fig. 4, red fluorescence). CX3CR1gfp fluorescent signals
arose from resident microglial cells sparsely distributed along three
retinal levels: at the ganglion cell, inner plexiform and outer
plexiform layers (Fig. 4, green fluorescence).
Labeling with anti-mCherry antibody revealed weak immmu-
noreactivity in the inner nuclear layer and strong in the ganglion
cell layer, consistent with the results obtained by in situ
hybridization and analysis of the mCherry reporter natural
fluorescence (Fig. S3).
Discussion
In order to characterize changes in fractalkine (CX3CL1)
expression in normal wt and with the progression of disease in
rd10 mice, we compared retinas at seven different ages. At P5,
when differentiation of retinal ganglion and amacrine cells and
their ongoing programmed apoptosis and cell clearance takes
Figure 2. Comparison of total CX3CL1 protein and mRNA expression levels in rd10 and wt retinas. (A). Western blot analyses of total
CX3CL1 protein levels in rd10 retinas compared to wt retinas determined in five independent experiments. Total protein levels in rd10 retinas are
significantly decreased at P10 and remain low at all time points examined. Results (mean 6 SEM, n = 5) are expressed as fold change over control in
densitometric arbitrary units. *P,0.0001 versus control. (B). Expression of CX3CL1 mRNA in wt and rd10 retinas at P5, P10, P14, P22, P30, P45 and P60,
determined by real-time PCR normalized to b-microglobulin levels. Comparable CX3CL1 mRNA expression level in control wt and rd10 retinas at P5,
P10 and lower levels at P14 and later time-points in rd10 retinas compare with wt retina. Values are mean 6 SEM (n= 5–7; *p,0.05; ns: not
significant).
doi:10.1371/journal.pone.0106562.g002
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place along with differentiation of horizontal cells, photoreceptors
and formation of the outer plexiform layer, and initiation of
conventional synapse production are almost complete in wt retina
[52–54]. At P10, when the interconnections of vertical retinal
networks are establishing, and bipolar cells are born and
connections with ganglion cells are established [52,54]; at eye-
opening when synaptic ribbons begin to form and conventional
synapses are produced at increased rate (P14) [52–54]; at the peak
of rod photoreceptor death in rd10 [39,51] and a sharp reduction
in the rate of production of both ribbons and conventional
synapses in wt (P22) [53]; at the initial disorganization of the loss in
size of rod bipolar cell terminals in rd10 (P30) [45]; after near
complete degeneration of rod photoreceptors, ongoing remodeling
of AII amacrine cells, a key cell type in the primary rod circuit [42]
resulting in near complete loss of rod bipolar cell responses in rd10
(P45) [44]; at the peak of cone photoreceptors degeneration and
before cone bipolar cells and ganglion cells degenerate in rd10
retina (P60) [41,43,44].
Fractalkine protein was shown to exist as two functionally
distinct forms: a cell-associated (membrane integrated) form and a
soluble (cleaved) form that has been proposed to arise by
processing of the membrane integrated protein [13,22,55,56].
The ,100 kDa CX3CL1 form found in our study, has been
suggested previously to represent the mature full-length form and
the only CX3CL1 form present at the cell surface, while the ,85-
kDa has been considered as a soluble CX3CL1 form. It was
suggested that CX3CL1 is initially synthesized as a 50–75 kDa
precursor, the form we did not detect in our immunoblots, that
undergoes glycosylation and transport to the cell surface as a
,100 kDa glycoprotein. This ,100 kDa CX3CL1 form then
could be released from the cell surface yielding a soluble ,85 kDa
fragment that likely contains the majority of the glycosylated
ectodomain, and a ,20 kDa transmembrane cytoplasmic domain
fragment [22]. The membrane integrated ,100-kDa band and a
soluble ,85-kDa CX3CL1 form were present in retinal lysates at
P5, both in wt and rd10 retinas and at P45 and P60 in rd10 retinas
only, indicating intensive CX3CL1 shedding. It has been
suggested that the equilibrium between the membrane integrated
and soluble forms of CX3CL1 plays an important role in
regulating the biological activity of this molecule [57] and
regulation of CX3CL1 cleavage may have a direct impact on
neuronal survival both in vitro and in vivo [18], as evident with
the injury of neurons or their exposure to glutamate, immediately
leading to shedding of CX3CL1 [26,57].
Figure 3. Localization of CX3CL1 mRNA expressing cells in the retina and brain of wt and rd10 mice. (A-D). Light micrographs of radial
cryosections through mouse central retina probed with a DIG-labeled anti-sense CX3CL1 riboprobe. In both, wt (A) and rd10 (B) mouse retinas,
CX3CL1 mRNA signal is present exclusively in the neurons of the ganglion cell layer (GCL) and the inner- and outermost areas of the inner nuclear
layer (INL). The outer nuclear (photoreceptor) layer is devoid of CX3CL1 signal at the time points examined (P22 and P30). Enlargements showing
juxtanuclear localization of mRNA in the cells of inner nuclear (C) and ganglion (D) cell layers in wt mouse retina. (E-G). Distribution of CX3CL1 mRNA
expressing neurons in wt mouse hippocampus. Light micrographs of a paraffin section used as positive control. (E). Numerous CX3CL1 mRNA-
positive neurons are located in all hippocampal subfields of the pyramidal (PCL) and in the dentate granule cell layers (GCL). (F). Higher magnification
of the dentate gyrus tips and of hilus. (G). Enlargement showing high levels of CX3CL1 mRNA expression within the grey matter of the cerebral cortex.
PCL, pyramidal cell layer; GCL, layer of ganglion cells in dentate granule cell layer; H, hilus; T, dentate gyrus tips. Cells expressing CX3CL1 mRNA are
visualized as of brown product accumulations in cryosections and red-brown in paraffin sections. The different color of nuclei staining (blue in
cryosections and purple in paraffin sections) is due to a hemalaun counterstaining. Scale bars represent: 50 mm (A, B), 35 mm (C, D), 250 mm (E),
125 mm (F) and 25 mm (G).
doi:10.1371/journal.pone.0106562.g003
Fractalkine Protein Expression in Mouse Retina
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e106562
The ,95 kDa protein band recognized by the same anti-
chemokine domain antibody used in our study represents the most
abundant band of CX3CL1 in both rd10 and wt retinas from P14
and the only protein form in wt retinas from P30 into young
adulthood (P60). The ,95 kDa protein accumulation may have
resulted from recycling of the membrane integrated form, as
fractalkine is a chemokine known to undergo internalization
serving to protect the chemokine from degradation by metallo-
proteases [58,59]. Indeed, mouse CX3CL1 was not only found at
the cell surface and in juxtanuclear compartments, where it is
presumably produced, but also in vesicle-like structures close to the
cell membrane. These vesicles were positive for the early
endosomal antigen 1 (EEA1) suggesting that CX3CL1 was
internalized via the endosomal pathway [60]. These results are
consistent with earlier reported findings that wild type CX3CL1
undergoes constitutive internalization via clathrin-coated pits and
is recycled to the cell surface [58]. There is experimental evidence
suggesting that the cytoplasmic domain of the protein is required
for efficient internalization of CX3CL1 from the cell surface
[59,60]. Therefore we may expect that the internalized form of
protein will have all the domains of the full-length protein and may
migrate as ,100 kDa form when extracted from the pool of
endocytic vesicles in the retina lysates, or migrate slightly further, if
it originates from a pool of the early endosomes, where it may
undergo endogenous processing.
In accordance with the idea that neurons in the retina may
accumulate pre-synthesized fractalkine, it has been previously
described that in steady state, roughly half the total cellular pool of
CX3CL1 is found intracellularly, and that the remaining fraction
is on the plasma membrane as demonstrated for cultured cells of
endothelial and epithelial origin, as well as for cultured fibroblasts
[58,59,61,62]. Indeed, in an earlier study, antibodies have been
used that specifically recognize only the amino- or the carboxyl-
terminal ends i.e., they allowed to distinguish between cleaved and
full-length membrane integrated human fractalkine [63]. This
property enabled to detect two closely migrating bands of similar
size at ,95 kDa within transfected cell lysates and a ,85–90 kDa
band that was found within the cell supernatants. According to the
authors, the two closely migrating bands (,95 kDa) represent
different glycosylated cell-associated forms and the smaller band
(,85–90 kDa) indicates a cleaved soluble form of the molecule.
Also, the two closely separated bands of ,100 kDa corresponding
to the cell-associated full-length mature fractalkine were clearly
shown, but not described, in another study where the cellular
processing of fractalkine and the mechanisms that lead to the
release of the soluble ectodomain were investigated (see Fig. 1 C
and Fig. 5 C in the publication [22]). On the other hand, in many
other studies, a band of ,95 kDa proved undetectable, possibly as
a result of variations in the cell types and experimental conditions
applied. The mechanism underlying the preferential localization of
CX3CL1 under normal physiological conditions to the intracel-
lular compartments in the mature retina is not clear.
Overall, in our study we show that there was a strong, positive
correlation between relative band intensities of the membrane
integrated and both, cleaved and presumably intraneuronal forms
of fractalkine protein, suggesting the possibility that a dynamic
equilibrium between the intracellular compartment and plasma
membrane regulates the availability and processing of fractalkine
at the cell surface.
Quantification of total CX3CL1 protein expression revealed
comparable levels in retinas of rd10 and wt mice shortly after birth
(P5). At later time-points, surprisingly from P10 that is before the
onset of morphological changes in rd10 retinas, total CX3CL1
protein levels were significantly lower compared to wt retinas.
Apparently, major neurochemical remodeling may occur prior to
anatomical remodeling at an early stage of retinal degeneration,
and likely accounting for the early decrease in fractalkine protein
level. At later time-points, a further decrease in CX3CL1 total
protein levels in rd10 retinas might be explained by a possible loss
of neurons, eventually from the ganglion and inner nuclear cell
layers, representing the main source of CX3CL1.
Although mRNA in degenerating rd10 retina is expressed at low
levels, it seems to be stable and efficiently translated. Changes in
the levels of CX3CL1 mRNA in rd10 and wt retinas detected by
real-time PCR in our study, largely coincided with changes of
CX3CL1 total protein expression, with the exception of P10,
where no differences in mRNA levels between rd10 and wt mice
have yet been detected. At P14 to P60, when change in mRNA
levels correlate with change in protein level, we could propose that
regulation of fractalkine gene expression is tightly controlled at the
levels upstream of translation.
Figure 4. Regionally restricted CX3CL1 expression in the retina
of adult CX3CL1 cherry: CX3CR1gfp mouse (A-E). Fluorescent
light microscopy analysis of a vertical retina cryosection (A) showing
both CX3CL1/Cherry (detected in rhodamine channel, red) (B) and
CX3CR1/GFP (detected in FITC channel, green) (C) reporters expression.
CX3CR1/GFP signal is assigned to microglial cells with cell bodies and
dendritic ramifications in three sublayers (outer plexiform layer, OPL,
inner plexiform layer, IPL and ganglion cells layer, GCL). CX3CL1/Cherry
fluorescent cells are found exclusively in ganglion cell and inner nuclear
layer. No fluorescent cells were observed in outer nuclear layer (ONL).
Enlargements show strong Cherry signal in a presumable amacrine cell
body in inner nuclear (D, arrow points to dendritic base) and ganglion
cell (E) layers, indicating high level of the CX3CL1 chemokine promotor
activity in neurons. Cryosections are counterstained with DAPI nucleic
acid stain (blue). Distribution of the Cherry reporter positive cells in the
retina of CX3CL1cherry: CX3CR1gfp mice coincides mostly with results
obtained in in situ hybridization studies. Of note, membrane/lipid inner
and outer photoreceptor segment layer exhibit nonspecific fluores-
cence. Scale bars represent 50 mm (A, B and C), and 10 mm (D, E).
doi:10.1371/journal.pone.0106562.g004
Fractalkine Protein Expression in Mouse Retina
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e106562
In rd1 mice, a model of RP bearing a point mutation of the b
phosphodiesterase gene in exon 7 and representing a more severe
form of RP, no significant changes in the levels of CX3CL1
mRNA during rod photoreceptor degeneration were detected
[64]. The determination of CX3CL1 mRNA expression in this
study was however accomplished using primers not separated by
introns and by a semi-quantitative PCR method only.
However, analysis of mRNA expression level due to the
posttranslational modifications cannot predict amount of the
functional CX3CL1 protein it encodes for. Importantly, the
identification of fractalkine forms in physiological and pathological
in vivo settings forms the ultimate proof that posttranslational
modification of the chemokine is relevant in regulating the
biological activity of this molecule.
The fractalkine signaling and survival system seems to be
regulated independently of the rod photoreceptor death; since
changes in expression levels of fractalkine mRNA and total protein
preceded the onset of degeneration (P16–18), while protein
regulation toward extensive production of soluble fractalkine
occurred at the late phase of rod degeneration (P30–45).
Our data collectively indicate that fractalkine is distinctively
expressed and regulated in rd10 denegerative retinas compared to
wild type retinas. Moreover, fractalkine protein is distinctively
regulated in healthy mature neural retina (P30–P60), with ,95-
kDa being the principal form compared to healthy brain in
particular, hippocampus, with ,100, ,95 and ,85 kDa forms
present. Notably, soluble fractalkine was found in early postnatal
retina (P5) and adult (P200) dentate gyrus, suggesting that soluble
form is required for the proper neurogenesis in both organs.
Significantly, neurons in the retina release increased levels of
soluble fractalkine when their health is compromised (P45–60).
Our data also suggest that the CX3CL1- CX3CR1 axis does
not seemingly respond to any form of photoreceptor death (e.g.
programmed cell death during development, rod and cone death
during degeneration). It rather appears post-translationally regu-
lated to modify the biological activity of CX3CL1 in case of
pathological changes possibly affecting only the neurons producing
fractalkine themselves. Indeed, programmed apoptosis and cell
clearance of ganglion and amacrine cells during postnatal retinal
development at around P5 and progressing remodeling of the
inner retina between P30 into young adulthood (P60) do correlate
with distinguished regulation of this signaling system suggesting
that fractalkine may control a survival pathway to support cell and
tissue integrity in times of need revealing a protective function of
microglial cells.
Interestingly, the reduction in fractalkine levels occurred several
days before the onset of rod photoreceptor death and weeks before
morphological signs of bipolar, amacrine, ganglion cells degener-
ation, suggesting that fractalkine regulation is a dynamic process
rather than a nonspecific consequence of neuronal death and of
changes in the microenvironment.
In the present study we further demonstrated by in situ
hybridization histochemistry, presence of CX3CL1 mRNA in
subpopulations of neurons of the inner nuclear layer and layer of
ganglion cells. Moreover, the distribution pattern of the Cherry
reporter positive cells in the retina of CX3CL1cherry:CX3CR1gfp
mice was consistent with the outcome of our in situ hybridization
studies. As pointed out in earlier study [20], the expression of the
cherry and gfp transgenes in CX3CL1cherry:CX3CR1gfp mice
reports on the respective promoter activities but not the actual
presence of the receptor/ligands, the fact particularly relevant with
respect to axon and dendrite-bearing neurons. In this respect we
may hypothesize that CX3CL1 protein may be expressed largely
in the dendrites of the neurons in the inner nuclear layer, in
particular, in the dendrites of bipolar cells (outermost area of the
INL). Indeed, recent studies [7,8] demonstrated a role of
fractalkine in interaction of microglia with dendritic synapses in
the CNS. Therefore, it is plausible to suggest that we may observe
strong CX3CL1 mRNA labeling in many neurons but the cherry
protein is expressed only in a few cell bodies in the INL of retina. It
is likely, that these cells represent amacrine and bipolar cell
subpopulations in both marginal-subtiers of the inner nuclear layer
(INL), and a subpopulation of ganglion cells in the ganglion cell
layer. However, the fact that displaced amacrine cells exist in the
ganglion cell layer [65–67] as well as a displaced ganglion cell
population in the inner nuclear layer [68] complicates interpre-
tation. Further studies will be needed to determine the exact types
of neurons expressing CX3CL1 in the mouse retina. Our data,
however, do not demonstrate detectable CX3CL1 expression in
the microvascular endothelial cells of the retinas of either rd10 or
wt mice, contrary to the situation reported for retinal explants of
human eyes [69].
The important question what role each form of the fractalkine
protein may play under normal and pathological conditions also
remains to be answered. Recent investigations in CX3CR1-
deficient animals showed a negative effect of this mutation for
adult neurogenesis and hippocampal circuit integrity [38,70].
Mice lacking CX3CR1 have a significant reduction in the density
of microglia during the postnatal period and exhibit transient
defects in synaptic connectivity and plasticity in the postnatal
hippocampus [7]. In accordance, another study further found that
CX3CR1-deficient mice display significant cognitive impairment
[71].
In the current literature the overall idea is that neurons control
microglial activity and a lack of CX3CL1-CX3CR1 interaction
leads to the ‘‘hyperactivity’’ of microglia unleashing potential
neurotoxic properties. However, the protective/neurotoxic role of
fractalkine and its receptor signaling in neurodegenerative disease
is an intricate and highly debated research topic and it is becoming
even more complicated as new studies reveal conflicting results
depending on the CNS insult [72–75]. Very recent data show,
however, protective effects of the fractalkine protein on retinal
structure and function. This is supported by the analysis of light-
injured rat retinas with transplanted mesenchymal stem cells
engineered to secrete CX3CL1 [76]. Here the CX3CL1-
expressing mesenchymal stem cells inhibited apoptosis of the
retinal cells and microglial activation. Additionally, as shown
during the revision of our manuscript, Peng et al. [77]
demonstrated, that microglia activation was an early alteration
in RP retinas in rd10 mice and that inhibition of microglia
activation by minocycline through both anti-inflammatory and
anti-apoptotic mechanisms reduced photoreceptor apoptosis,
significantly protecting retinal structure, function and visual
behavior. Furthermore, CX3CR1 deficiency in double knockout
Rd10/CX3CR1-/- mice dysregulated microglia activation and
subsequently resulted in increased photoreceptor vulnerability.
Altogether these results suggest that the CX3CL1/CX3CR1
signaling pathway might protect against microglia neurotoxicity.
In summary, our results demonstrate that fractalkine ligand is
differentially expressed under physiological and neurodegenerative
conditions. It is continuously expressed by subpopulations of
retinal neurons and exists at least in three different forms. The
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individual signaling functions of each CX3CL1 isoform in the
retina should become a topic for future research.
Supporting Information
Figure S1 Control experiments of anti-CX3CL1 anti-
body signal specificity (A-F) and sex-related differences
(G-L). (A). Representative example of Western blots of rd10
retina at P60 (left lane) and wt mouse dentate gyrus at P200
(positive control, right lane) showing the three bands of CX3CL1
protein: 100-kDa, 95-kDa and 85-kDa. (B). 10 ng of recombinant
human peptide (aa 25-100) migrated as a 70 kDa band. (C-E).
Antigen-peptide neutralization (competition) assay. (C). Upon
control peptide addition, a 95-kDa band is completely depleted in
wt retina sample at P45. (D). 100-kDa, 95-kDa and 85-kDa bands
are completely depleted in rd10 retina sample at P45. (E). Band
85-kDa is depleted and bands 100-kDa and 95-kDa are
significantly diminished in wt mouse dentate gyrus sample at
P200. – no peptide (left lanes), + peptide (right lanes). (F). No
primary antibody control. (G-L). Representative examples of the
Western blots of wt and rd10 retinas at P22 and P45. No sex-
related differences in signal pattern of both specific and nonspecific
bands were observed at all age groups examined. F-female, M-
male.
(TIF)
Figure S2 Western blot analyses of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) protein expression
in rd10 and wt mouse neuroretina. Relative intensity of
GAPDH signal detected by loading 10 mg of total protein per lane
in wt and rd10 retina lysates at P5 to P60. Values (mean 6 SEM,
n=5) are expressed in densitometric arbitrary units. Ns -
difference is not statistically significant. Data are representative
of five experiments.
(TIF)
Figure S3 Representative cryostat section of
CX3CL1cherry: CX3CR1gfp transgenic adult mouse
retina immunostained with antibodies against mCherry
(green) and GFP (red). Dual immunoreactivity (A) showing the
mCherry signal in inner nuclear (INL) and ganglion cell (GCL)
layers, largely coinciding with results obtained by in situ
hybridization studies, shown here as insert of rd10 section at
P22 (B). CX3CLl/Cherry detected in FITC channel (C).
Cryosections were counterstained with DAPI nucleic acid stain
(D). CX3CL1/GFP detected in rhodamine channel (E). Outer
nuclear (ONL) and inner plexiform (IPL) layers are devoid of
specific signal. Of note, blood vessels are co-labeled due to mouse-
on-mouse immunolabeling without blocking of endogenous IgGs.
However, both primary and secondary antibodies controls
exhibited no immunolabelling. Scale bars (A-E) represent 50 mm.
(TIF)
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